# Agent 1 Benchmark Report - 02_ct_analysis

**Generated:** 2026-06-03 12:46:31
**Agent:** 1
**Category:** 02_ct_analysis

## Executive Summary

| Metric | Value |
|--------|-------|
| Total Tests | 88 |
| Passed | 72 |
| Failed | 16 |
| Pass Rate | 81.8% |
| Avg Score | 0.812 |

### Failure Root Causes

| Root Cause | Count | % of Failures | Severity |
|------------|-------|---------------|----------|
| too_brief | 11 | 68.8% | P2 |
| language_mismatch | 2 | 12.5% | P1 |
| wrong_answer | 2 | 12.5% | P2 |
| keyword_missing | 1 | 6.2% | P2 |

## Detailed Results

### ❌ Q0076

**Input:** I have uploaded a CT scan for a prostate cancer patient. The scan was acquired with 3mm slice thickness and includes the pelvis from the iliac crests to the ischial tuberosities. Please analyze the image quality, identify the prostate gland, and assess whether the scan quality is sufficient for brachytherapy planning....

**Response:**
> Tools executed. Check the execution trace above for results....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0076](../screenshots/02_Q0076.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (60 chars)

---

### ❌ Q0077

**Input:** This CT scan shows a patient with cervical cancer. I need you to evaluate the tumor extent visible on CT, identify the tandem and ovoid applicator that was placed under anesthesia, and assess the applicator position relative to the cervix and uterus. Please provide measurements of the applicator geometry....

**Response:**
> Tools executed. Check the execution trace above for results....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0077](../screenshots/02_Q0077.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (60 chars)

---

### ❌ Q0078

**Input:** I uploaded a CT scan of a patient scheduled for prostate seed implant. The scan was done in the lithotomy position with a ultrasound probe in place. Please identify the prostate, seminal vesicles, bladder, and rectum, and provide approximate volumes for each structure....

**Response:**
> Let me check if a CT scan is currently loaded and analyze the prostate brachytherapy case....

**Scores:**
- Total: 0.62
- Keyword: 0.20
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0078](../screenshots/02_Q0078.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (90 chars)

---

### ❌ Q0079

**Input:** Please analyze this head and neck CT scan for a patient with oral tongue carcinoma. I need to assess the extent of the primary tumor, evaluate lymph node involvement, and determine if there is mandibular invasion visible on CT....

**Response:**
> Let me check if a CT scan is currently loaded and perform the analysis....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0079](../screenshots/02_Q0079.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (71 chars)

---

### ❌ Q0080

**Input:** This is a chest CT scan for a patient with endobronchial tumor who may be a candidate for endoluminal brachytherapy. Please evaluate the tumor location, degree of luminal obstruction, proximity to the carina, and identify any atelectasis or post-obstructive changes....

**Response:**
> Let me check if a chest CT scan is currently loaded in the system....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0080](../screenshots/02_Q0080.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (66 chars)

---

### ❌ Q0081

**Input:** I have uploaded a post-implant CT scan for a prostate brachytherapy patient. The scan was taken 30 days after I-125 seed implantation. Please analyze the seed distribution, identify any seed migration to the lungs, and provide an assessment of overall implant quality....

**Response:**
> Let me check if a CT scan is currently loaded in the system....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0081](../screenshots/02_Q0081.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (60 chars)

---

### ✅ Q0082

**Input:** Please examine this CT scan of a rectal cancer patient. The patient has a T3N1 rectal adenocarcinoma located 5cm from the anal verge. Assess the relationship of the tumor to the mesorectal fascia, evaluate for extramural vascular invasion, and determine the distance from the tumor to the anal sphincter....

**Response:**
> **No CT scan is currently loaded** in the system. However, I can provide a clinical assessment framework for this rectal cancer case:## Clinical Assessment: Rectal Cancer for Brachytherapy Boost### Case Summary- T3N1 rectal adenocarcinoma- 5 cm from anal verge- Post-nCRT evaluation for brachytherapy boost candidacy### Key CT Findings to Evaluate| Parameter | Assessment ||-----------|------------|| **Mesorectal fascia involvement** | If >1mm from MRF, consider brachytherapy boost || **Extramural vascular invasion (EMVI)** | Present = higher recurrence risk || **Tumor to anal sphincter** | 5 cm = borderline for transanal access || **Pelvic lymphadenopathy** | N1 disease confirmed |### Brachytherapy Candidacy**Favorable for boost:**- Complete or near-complete response- Clear MRF margin (>1mm)- Tumor accessible trans...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0082](../screenshots/02_Q0082.png)

---

### ❌ Q0083

**Input:** This CT scan shows a breast cancer patient being considered for APBI. The lumpectomy cavity is visible in the upper outer quadrant of the left breast. Please identify the cavity, measure its dimensions, assess the chest wall distance, and evaluate the skin-to-cavity distance for balloon placement feasibility....

**Response:**
> Let me check if a CT scan is currently loaded in the system....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0083](../screenshots/02_Q0083.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (60 chars)

---

### ❌ Q0084

**Input:** I have a CT scan for a patient with recurrent endometrial cancer at the vaginal cuff. The CT shows some soft tissue thickening at the cuff. Please analyze the extent of the recurrence, evaluate the relationship to the bladder and rectum, and assess whether brachytherapy is feasible....

**Response:**
> Tools executed. Check the execution trace above for results....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0084](../screenshots/02_Q0084.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (60 chars)

---

### ✅ Q0085

**Input:** Please analyze this CT scan for a patient with a penile cancer. The scan shows an exophytic lesion on the glans penis. Evaluate the depth of invasion, assess for inguinal lymph node involvement, and determine if the tumor is amenable to organ-preserving brachytherapy....

**Response:**
> ## Penile Cancer Assessment for Brachytherapy EligibilityI cannot analyze a CT scan because **no files are currently loaded**. However, I can provide guidance on the clinical assessment criteria for organ-preserving brachytherapy in penile cancer.---### 1. Depth of Invasion Assessment| Parameter | Evaluation Method | Clinical Significance ||-----------|------------------|----------------------|| **T stage** | MRI is superior to CT for soft tissue distinction | T1: ≤5mm or ≤T2 (lamina propria) || **Lesion thickness** | Measure from basement membrane to deepest invasion | Brachytherapy optimal for T1-T2, selected T3 || **Corpus spongiosum invasion** | Key determinant for brachytherapy | Invasion into corpus spongiosum increases failure risk || **Cavernosal invasion** | If present, generally excludes organ preservation | T4 or...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0085](../screenshots/02_Q0085.png)

---

### ✅ Q0086

**Input:** This CT scan is from a patient with biliary tract cancer. I need to evaluate the tumor extent along the bile duct, assess vascular involvement of the portal vein and hepatic artery, and determine if interstitial brachytherapy can be safely performed....

**Response:**
> ## Response### ⚠️ No CT Files LoadedI cannot analyze the CT scan or perform image-based evaluation because **no CT files are currently loaded in the system**.**To proceed with your biliary tract cancer evaluation, please upload the CT scan first**, then I can assist with:- Tumor extent assessment- Vascular involvement analysis- Safety evaluation for interstitial brachytherapy---### Clinical Guidance (Knowledge-Based)While I cannot analyze the specific images, here's what to evaluate for biliary tract brachytherapy planning:**Tumor Extent Evaluation:**- Review contrast-enhanced CT in portal venous phase for ductal involvement- Assess proximal/distal extent along bile duct- Check for biliary obstruction level (hilar vs. distal)**Vascular Involvement Assessment:**| Structure | Key Findings to Evaluate ||-----------|--------------------------|| Portal vein | Degree of encasement (<180...

**Scores:**
- Total: 0.91
- Keyword: 0.75
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0086](../screenshots/02_Q0086.png)

---

### ❌ Q0087

**Input:** I have uploaded a CT scan for a patient with a vulvar melanoma. The primary lesion is on the right labium majus. Please evaluate the tumor dimensions, depth of invasion, assess for groin lymph node metastases, and determine if interstitial brachytherapy is appropriate for this patient....

**Response:**
> I'll first check if the CT scan files are available in the system....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0087](../screenshots/02_Q0087.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (66 chars)

---

### ✅ Q0088

**Input:** Please analyze this CT scan of a pediatric patient with a bladder rhabdomyosarcoma. The patient is 4 years old. Evaluate the tumor extent, assess bladder wall invasion, evaluate for hydronephrosis, and determine if brachytherapy boost is indicated alongside external beam....

**Response:**
> No CT scan is currently loaded in the system. I cannot perform image analysis without uploaded files.**To proceed, please:**1. Upload the CT scan DICOM files for this 4-year-old patient with bladder rhabdomyosarcomaOnce uploaded, I can evaluate:- Tumor extent and dimensions- Bladder wall invasion depth- Hydronephrosis (present/absent, severity)- Perivesical fat involvement- Lymph node status**In the meantime, here's what I can tell you from clinical knowledge:**For pediatric bladder rhabdomyosarcoma (typically embryonal subtype in this age group):| Parameter | Typical Findings ||-----------|------------------|| Common site | Bladder dome/trigone || Stage | Usually group III (incomplete resection) at presentation || Bladder preservation | ~70-80% with multimodal approach |**Brachytherapy boost indications:**- Residual disease after chemotherapy (± conservative surgery)- Favorable for bladder preservation- Typical dose: 14-21 Gy (after 41.4 Gy EBRT)- Volume should...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0088](../screenshots/02_Q0088.png)

---

### ❌ Q0089

**Input:** This CT scan shows a patient with advanced cervical cancer being evaluated for brachytherapy. There is a large cervical mass with parametrial extension. Please assess the tumor volume, evaluate the relationship to the pelvic sidewall, and measure the distance to the ureters....

**Response:**
> I need to check if CT files are loaded before I can analyze the scan....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0089](../screenshots/02_Q0089.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (69 chars)

---

### ✅ Q0090

**Input:** I have uploaded a CT scan for a prostate cancer patient with a large prostate volume of approximately 80cc. Evaluate the prostate size, assess for median lobe protrusion into the bladder, and discuss whether this patient is suitable for brachytherapy or if neoadjuvant hormonal therapy should be considered....

**Response:**
> No CT files are currently loaded in the system. I'll answer your clinical question from medical knowledge.## Prostate Volume Considerations for Brachytherapy (80cc Prostate)### Volume AssessmentFor HDR/LDR prostate brachytherapy:- **Optimal volume**: 20–50 cc- **Borderline**: 50–60 cc- **Large/technically challenging**: >60 cc- **Relative contraindication**: >80 cc (varies by institution)An **80cc prostate** is at the upper limit and presents several challenges:### Challenges with Large Prostates1. **Intraoperative difficulty** — Larger gland makes needle placement more complex2. **Increased pubic arch interference** — Higher risk of pubic bone collision3. **Dosimetric limitations** — Peripheral seeds harder to place;...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0090](../screenshots/02_Q0090.png)

---

### ✅ Q0091

**Input:** Please analyze this CT scan of a patient with a skin cancer on the nose. The lesion is a 2cm squamous cell carcinoma. Evaluate the depth of invasion on CT, assess cartilage involvement, and determine if surface brachytherapy with a custom mold is feasible....

**Response:**
> **No CT files are currently loaded.** I'll answer from clinical knowledge about this scenario.---## Nasal SCC Evaluation for Surface Brachytherapy### CT Assessment LimitationsCT has **limited sensitivity** for superficial skin cancers:- **Depth of invasion**: CT can visualize lesions ≥3-4mm depth; superficial invasion (<2mm) is often not detectable- **Cartilage involvement**: CT is reasonable for this — look for focal erosion, sclerosis, or destruction of nasal cartilage- **Perichondrial plane obliteration** suggests invasionFor a 2cm nasal SCC, recommended imaging:- **High-resolution CT** (1mm slices) with soft tissue and bone windows- **MRI with T2/STIR** if deeper invasion suspected...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0091](../screenshots/02_Q0091.png)

---

### ✅ Q0092

**Input:** This CT scan is for a patient with esophageal cancer at the gastroesophageal junction. Evaluate the tumor length, assess the degree of luminal narrowing, evaluate for mediastinal lymphadenopathy, and determine if endoluminal brachytherapy boost is appropriate....

**Response:**
> I don't have access to a CT scan loaded in the system. Based on your question, I'll provide guidance on esophageal cancer evaluation at the gastroesophageal junction and endoluminal brachytherapy indications.## Esophageal Cancer at GE Junction: Evaluation for Brachytherapy### Tumor Length Assessment- Measure craniocaudal extent on contrast-enhanced CT (typically >2 cm length suggests more advanced disease)- Correlate with endoscopic ultrasound (EUS) for accurate T-stage and length- GE junction tumors often involve the proximal stomach (Siewert classification important)### Luminal Narrowing- **Mild**: >50% lumen patent — brachytherapy generally feasible- **Moderate**: 25-50% patent — may require dilation prior to applicator placement- **Severe**: <25% patent or dysphagia to saliva — contraindication to applicator passage; EBRT preferred### Mediastinal Lymphadenopathy- Target: Peries...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0092](../screenshots/02_Q0092.png)

---

### ✅ Q0093

**Input:** I uploaded a CT scan showing a patient with liver metastases from colorectal cancer. There are two lesions in the right hepatic lobe. Please segment the lesions, measure their volumes and positions relative to the hepatic vasculature, and assess whether image-guided brachytherapy is feasible....

**Response:**
> No CT files are currently loaded in the system. I cannot perform segmentation or image analysis without uploaded scan data.However, I can provide guidance on evaluating liver metastases for brachytherapy feasibility based on the typical workflow:## Liver Metastasis Brachytherapy Evaluation**Key imaging parameters to assess:**- Lesion number, size, and volume- Distance from hepatic vasculature (portal vein, hepatic artery, hepatic veins)- Segment location (Couinaud classification)- Proximity to adjacent organs (kidneys, colon, stomach)**Feasibility criteria for image-guided brachytherapy:**| Factor | Favorable | Unfavorable ||--------|-----------|-------------|| Size | <3 cm | >5 cm || Location | Peripheral, away from central vessels | Central/hilar || Number | 1-3 lesions | >5 lesions || Liver function | Preserved (...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0093](../screenshots/02_Q0093.png)

---

### ✅ Q0094

**Input:** Please analyze this CT scan for a patient with an anal canal cancer. The tumor is located at the dentate line. Evaluate the tumor extent, assess involvement of the internal and external sphincters, and determine if brachytherapy boost is indicated after external beam radiation....

**Response:**
> No CT scan is currently loaded in the system. However, I can provide guidance on what to evaluate and the criteria for brachytherapy boost in anal canal cancer based on established clinical knowledge:## CT Evaluation Criteria for Anal Canal Cancer### Tumor Extent Assessment- **Length measurement**: Measure craniocaudal extent from dentate line- **Circumferential involvement**: Estimate percentage of canal circumference involved- **Proximal extension**: Assess extension into distal rectum- **Distal extension**: Evaluate spread toward anal verge### Sphincter Involvement| Structure | Key Features on CT | Clinical Significance ||-----------|-------------------|----------------------|| **Internal sphincter** | Involuntary smooth muscle, located within 2 cm of dentate line | Sphincter preservation if spared || **External sphincter** | Voluntary striated muscle, distal to dentate line | Critical for continence |...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0094](../screenshots/02_Q0094.png)

---

### ❌ Q0095

**Input:** This CT scan shows a patient with head and neck cancer requiring interstitial brachytherapy. There is a recurrent tumor in the floor of mouth. Please evaluate the tumor dimensions, assess mandibular proximity, evaluate the sublingual gland position, and determine optimal needle placement zones....

**Response:**
> 我没有加载任何CT扫描文件。让我从临床知识出发，为您提供关于口腔底复发肿瘤近距离放疗计划的详细指导。---## 口腔底复发肿瘤 - 间质性近距离放疗计划### 临床背景口腔底（FOM）肿瘤靠近下颌骨、舌体和重要血管神经结构，需要仔细评估以优化针道置入并避免并发症。---### 1. 肿瘤评估要点| 参数 | 评估内容 ||------|----------|| **大小** | 测量三个径线（前后、左右、头尾） || **深度** | 浸润深度至舌肌或下颌骨骨膜 || **边界** | 与下颌牙槽嵴的距离 || **邻近结构** | 舌下腺、颏神经、舌动脉 |### 2. 下颌骨邻近性评估- **安全距离**：针道距下颌骨皮层应 ≥5 mm，避免骨坏死...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0095](../screenshots/02_Q0095.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q0096

**Input:** I have a CT scan for a female patient with a vaginal melanoma. The tumor is in the upper third of the vagina. Please evaluate the tumor extent, assess the relationship to the bladder and rectum, evaluate for lymph node involvement in the pelvis, and determine brachytherapy feasibility....

**Response:**
> Based on the current system state, no CT files are loaded. However, I can provide guidance on vaginal melanoma evaluation and brachytherapy feasibility from clinical knowledge:## Vaginal Melanoma - CT Evaluation Framework**Tumor Assessment:**- Upper third vaginal melanomas have better prognosis than lower third- Measure maximal tumor dimensions in axial, sagittal, and coronal planes- Evaluate mucosal involvement length and depth of invasion- Assess for multifocal disease (melanoma can be patchy)**Critical Structure Relationships:**| Structure | Evaluation Points ||-----------|-------------------|| Bladder | Minimum distance to bladder wall; look for focal bulge or invasion || Rectum | Distance to rectal wall; assess for rectal involvement || Urethra | Proximity for urethral dose constraints || Vaginal wall | Circumferential extent (% of circumference) |**Lymph Node Assessment:**- Inguinal nodes...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0096](../screenshots/02_Q0096.png)

---

### ✅ Q0097

**Input:** This is a post-implant CT scan taken at day 1 for a prostate brachytherapy patient. Please analyze the seed positions, evaluate edema by comparing with the pre-implant prostate volume, and provide an edema-corrected dosimetric assessment....

**Response:**
> I don't see any CT files currently loaded in the system.**To proceed with the post-implant analysis, please confirm the upload is complete.**In the meantime, here's what I can offer from clinical knowledge:---## Post-Implant Prostate Brachytherapy Analysis (Day 1)### Key Parameters to Assess:| Metric | Target | Notes ||--------|--------|-------|| **D90** | >100% prescription | Most critical dosimetric endpoint || **V100** | >95% prostate volume | Minimum acceptable coverage || **V150** | 50-60% | Prostate hotspot indicator || **Urethra D30, D10** | <150% / <200% | Urethral tolerance limits || **Rectum V100** | <1 cc | Strict rectal dose constraint |### Seed Position Evaluation:- Check for seeds in peri-prostatic region (expected...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0097](../screenshots/02_Q0097.png)

---

### ✅ Q0098

**Input:** Please analyze this CT scan for a patient with a recurrent tumor at the anastomosis after rectal cancer surgery. The recurrence is at the colorectal anastomosis. Evaluate the tumor volume, assess invasion into surrounding pelvic structures, and determine if interstitial brachytherapy can be safely delivered....

**Response:**
> 我将分析已上传的CT扫描图像，评估直肠癌术后吻合口复发病灶。## CT Analysis: Rectal Cancer Anastomotic RecurrenceBased on the available imaging data, here is the analysis for the recurrent tumor at the colorectal anastomosis:### Tumor Volume Assessment- **Location**: Pelvis, at surgical anastomosis- **Expected findings**: Soft tissue density at anastomotic site- **Key measurements needed**: Longitudinal length, wall thickness, cross-sectional area### Surrounding Structure Invasion Evaluation| Structure | Assessment Required ||-----------|---------------------|| **Anterior** | Bladder base, prostate (males), vagina (females) || **Posterior** | Presacral space, sacrum || **L...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0098](../screenshots/02_Q0098.png)

---

### ❌ Q0099

**Input:** This CT scan is for a patient with a urethral cancer. Please evaluate the tumor extent along the urethra, assess bladder involvement, evaluate for pelvic lymph node metastases, and determine if brachytherapy is appropriate for this rare malignancy....

**Response:**
> I'll check if CT scan files are loaded in the system....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0099](../screenshots/02_Q0099.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (53 chars)

---

### ❌ Q0100

**Input:** I have uploaded a CT scan for quality assurance purposes. This is a CTCAE phantom scan with known dimensions. Please verify the geometric accuracy of the CT by measuring the phantom dimensions and comparing them to the known specifications to validate spatial calibration....

**Response:**
> Error: Runtime error: name 'Exception' is not definedTraceback (most recent call last):  File "<brachybot_code>", line 8, in <module>  File "/home/lht/.conda/envs/brachytherapy/lib/python3.12/site-packages/SimpleITK/extra.py", line 384, in ReadImage    return reader.Execute()           ^^^^^^^^^^^^^^^...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0100](../screenshots/02_Q0100.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ✅ Q0846

**Input:** Describe the MRI protocol optimization for cervical cancer brachytherapy planning. What sequences are recommended for optimal soft tissue visualization, how should the imaging parameters be set for different MRI field strengths (1.5T vs 3T), and what are the specific requirements for imaging with the brachytherapy applicator in place?...

**Response:**
> ## MRI Protocol for Cervical Cancer Brachytherapy Planning### Recommended Sequences| Sequence | Purpose | Key Parameters ||----------|---------|----------------|| **T2-weighted (T2W)** | Primary sequence for soft tissue visualization | Turbo spin echo, high-resolution || **T1-weighted (T1W)** | Anatomy baseline, hemorrhage assessment | Spin echo || **DWI/ADC** | Tumor viability, treatment response | b-values 0, 500-1000 s/mm² || **Dynamic contrast (DCE)** | Optional: tumor perfusion | 3D gradient echo, temporal resolution <5s |### Field Strength Comparison| Parameter | 1.5T | 3T ||-----------|------|-----|| **SNR** | Baseline | ~1.5-2× higher || **T2W TR/TE** | 3000-4000/80-100 ms | 2500-3500/100-120 ms || **Spatial resolution** | 3...

**Scores:**
- Total: 0.95
- Keyword: 0.86
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0846](../screenshots/02_Q0846.png)

---

### ✅ Q0847

**Input:** Explain how diffusion-weighted MRI (DW-MRI) can be used to improve target volume definition in cervical cancer brachytherapy. How does the apparent diffusion coefficient (ADC) correlate with tumor biology and treatment response? What are the limitations of DW-MRI in the post-treatment setting, and how can this information improve adaptive treatment planning?...

**Response:**
> ## Diffusion-Weighted MRI in Cervical Cancer Brachytherapy### How DW-MRI Improves Target Volume Definition**Biological Target Volume (BTV) Concept:**- DW-MRI visualizes tumor cellularity rather than just anatomical boundaries- Restricted diffusion (low ADC) highlights hypercellular viable tumor- Can identify residual disease not visible on T2-weighted images- Allows distinction between tumor and post-radiation fibrosis**Practical Application:**- Fuse DW-MRI with T2-weighted images for composite target definition- Areas of restricted diffusion within the T2-defined tumor may require dose escalation- Can help define involved lymph nodes (high signal on b800-1000 images)### ADC Correlation with Tumor Biology| ADC Value | Interpretation | Clinical Significance ||-----------|----------------|----------------------|| **Low ADC (<0.8-1.0 × 10⁻³ mm...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0847](../screenshots/02_Q0847.png)

---

### ❌ Q0848

**Input:** Describe the CT imaging protocol for brachytherapy planning, including considerations for slice thickness, reconstruction kernels, contrast enhancement, and scan range. How do CT imaging parameters affect the accuracy of applicator reconstruction and dose calculation? What are the specific CT requirements for different applicator types?...

**Response:**
> ## CT Imaging Protocol for Brachytherapy Planning### General PrinciplesCT remains the standard for brachytherapy planning due to its universal availability, geometric accuracy, and excellent visualization of applicators and bones. Key considerations:---### 1. Slice Thickness| Application | Recommended Slice Thickness | Rationale ||-------------|---------------------------|-----------|| **Gynecological ( tandem/ovoid/ring)** | 2–3 mm | Balances volume coverage with applicator visibility || **Prostate interstitial** | 1–2 mm | Small seeds require high resolution || **Surface molds** | 2–3 mm | Moderate resolution sufficient || **Chest wall/breast** | 2–3 mm | Standard thoracic protocols |**...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0848](../screenshots/02_Q0848.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q0849

**Input:** Explain the process of CT-MRI image fusion for brachytherapy planning. What are the different registration methods (rigid, deformable), how do you evaluate registration accuracy, what are the common sources of registration error, and how does registration accuracy affect the clinical brachytherapy plan?...

**Response:**
> ## CT-MRI Image Fusion for Brachytherapy Planning### 1. Registration Methods#### Rigid Registration- **Definition**: Assumes a consistent spatial relationship between structures (no deformation)- **Application**: Primary method for applicator-based brachytherapy (cervical, prostate)- **Techniques**:   - Mutual information maximization (preferred for CT-MRI)  - Normalized cross-correlation  - Landmark-based (fiducial markers, applicator markers)- **Degrees of freedom**: Translation (3), rotation (3)#### Deformable Registration- **Definition**: Allows local warping to account for tissue deformation- **Application**: When significant anatomical changes occur between scans- **Techniques**:  - Demons algorithm  - B-spline registration  - Deep learning-based methods (e.g., Voxelmorph)- **Clinical use**: Not routinely recommended for brachytherapy due to dose calculation concerns---### 2. Evaluating Registration Accuracy| Method | Description | Acceptable Tolerance ||--------|-------------|--...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0849](../screenshots/02_Q0849.png)

---

### ✅ Q0850

**Input:** Describe the use of PET-CT imaging in brachytherapy planning for head and neck cancers. How can FDG-PET improve GTV delineation compared to CT and MRI alone? What are the specific PET artifacts caused by brachytherapy applicators, and how do you account for these artifacts in treatment planning?...

**Response:**
> ## PET-CT Imaging in Head and Neck Brachytherapy Planning### Value of FDG-PET for GTV DelineationFDG-PET improves target volume definition in head and neck brachytherapy through several mechanisms:| Advantage | Clinical Benefit ||-----------|------------------|| **Metabolic activity** | Identifies biologically active tumor beyond structural boundaries || **Lymph node staging** | Detects involved nodes missed on CT/MRI (sensitivity ~80-90% for nodes >1cm) || **Unknown primary** | Helps identify primary tumor when physical exam/imaging negative || **Delineation guidance...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0850](../screenshots/02_Q0850.png)

---

### ✅ Q0851

**Input:** Explain the concept of functional MRI (fMRI) for brachytherapy planning. How can perfusion MRI and diffusion-weighted imaging improve the assessment of tumor hypoxia and treatment resistance? What is the current evidence for using functional MRI to guide dose painting in brachytherapy?...

**Response:**
> ## Functional MRI for Brachytherapy Planning### OverviewFunctional MRI techniques—including perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), and blood oxygenation level-dependent (BOLD) imaging—provide metabolic and physiological information beyond anatomical imaging, potentially enabling biologically-guided dose prescription in brachytherapy.---### 1. Perfusion MRI for Tumor Hypoxia Assessment**Dynamic Contrast-Enhanced MRI (DCE-MRI)**- Measures microvascular permeability, blood flow, and volume- Key parameters: K^trans^ (volume transfer constant), v_e (extravascular extracellular space), v_p (plasma volume)- **Hypoxic tumors** show delayed enhancement and washout patterns- Low perfusion correlates with radioresistance due to reduced oxygen delivery**Dynamic Susceptibility Contrast (DSC-M...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0851](../screenshots/02_Q0851.png)

---

### ✅ Q0852

**Input:** Describe the challenges of imaging for brachytherapy in the presence of metallic implants (hip prostheses, surgical clips, dental fillings). What artifact reduction techniques are available for CT, MRI, and PET imaging? How do these artifacts affect applicator reconstruction and dose calculation accuracy?...

**Response:**
> ## Metallic Artifacts in Brachytherapy Imaging### Imaging Challenges by Modality| Modality | Primary Challenge | Effect on Brachytherapy ||----------|------------------|------------------------|| **CT** | Beam hardening, photon starvation | Applicator visibility obscured, HU distortion near seeds/clips || **MRI** | Signal void, spatial distortion | Inaccurate source localization, deformed anatomy || **PET** | Attenuation correction errors | Inaccurate tumor metabolic volume |---### CT Artifact Reduction Techniques**1. Metal Artifact Reduction (MAR) Algorithms**- **Iterative reconstruction**: Reduces beam hardening artifacts (available in modern scanners)- **Monoenergetic reconstructions**: Dual-energy CT can reconstruct at optimal keV (typically 70-90 keV effective)- **Vendor-specific...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0852](../screenshots/02_Q0852.png)

---

### ✅ Q0853

**Input:** Explain the role of transrectal ultrasound (TRUS) in prostate brachytherapy planning. How does TRUS imaging compare to CT and MRI for prostate volume measurement and applicator guidance? What are the specific advantages of TRUS for real-time guidance during prostate brachytherapy applicator placement?...

**Response:**
> ## Transrectal Ultrasound (TRUS) in Prostate Brachytherapy### Role of TRUSTRUS is the **primary imaging modality** for permanent seed prostate brachytherapy, used for:- Pre-implant prostate volume measurement- Real-time needle guidance during implantation- Post-implant dosimetry verification### TRUS vs. CT vs. MRI Comparison| Feature | TRUS | CT | MRI ||---------|------|-----|-----|| **Prostate Volume** | Gold standard (±5-10%) | Good (±10-15%) | Excellent (±5%) || **Soft Tissue** | Good | Moderate | Excellent || **Seed Visibility** | Poor | Excellent | Moderate || **Real-Time Guidance** | Yes | No | Limited || **Cost/Availability** | Low | Moderate | High || **Radiation** | None | Low dose | None |### TRUS Advantages for Real-Time Guidance1. **Dynamic needle visualization**: Track needle trajectory and depth in real-time2. **Immediate...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0853](../screenshots/02_Q0853.png)

---

### ✅ Q0854

**Input:** Describe the use of cone-beam CT (CBCT) imaging for brachytherapy setup verification. How does CBCT compare to kV imaging for applicator position verification? What are the specific image quality limitations of CBCT in the pelvis, and how can these be mitigated to improve verification accuracy?...

**Response:**
> ## Cone-Beam CT (CBCT) for Brachytherapy Setup Verification### CBCT vs. kV Imaging Comparison| Feature | CBCT | kV Imaging ||---------|------|------------|| **3D information** | Yes - volumetric | No - planar only || **Soft tissue visualization** | Moderate - improved with contrast | Poor || **Applicator reconstruction** | Direct 3D localization | Requires 2D marker identification || **Dose calculation** | Can estimate attenuation | No dose estimation || **Acquisition time** | Longer (10-30 sec) | Rapid (<5 sec) || **Radiation dose** | Higher (~5-20 mGy) | Lower (<1 mGy) || **Metal artifact** | More pronounced | Less artifact |### Pelvic CBCT Limitations**1. Image Quality Issues**- **...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0854](../screenshots/02_Q0854.png)

---

### ❌ Q0855

**Input:** Explain the concept of on-line adaptive brachytherapy using real-time MRI imaging. How does the MRI-linac platform enable adaptive brachytherapy? What are the current technical limitations, the evidence for online adaptive approaches, and how do they differ from offline adaptive strategies?...

**Response:**
> # 在线自适应近距离放疗：实时MRI引导技术## 一、核心概念**在线自适应近距离放疗（Online Adaptive Brachytherapy）** 是指在每次治疗分次前，基于当日实时影像即刻修改治疗计划的技术。与传统"离线"工作流程（先扫描、再计划、隔日治疗）不同，在线自适应实现了**当日成像-当日计划-当日治疗**的闭环。关键特征：- **时间点**：患者在治疗床上、施源器已放置、麻醉未醒- **适应范围**：靶区体积变化（肿瘤退缩、水肿）、器官位置偏移- **决策周期**：数分钟至20分钟内完成计划修改---## 二、MRI-linac平台在近距离放疗中的应用### 2.1 平台类型| 平台 | 代表系统 |...

**Scores:**
- Total: 0.77
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Q0855](../screenshots/02_Q0855.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ✅ Q0856

**Input:** Describe the quality assurance procedures for MRI-based brachytherapy imaging. What phantom tests are needed to verify MRI geometric accuracy, signal uniformity, and image distortion? How do you validate that the MRI imaging chain does not introduce clinically significant errors in applicator reconstruction and target delineation?...

**Response:**
> # MRI Quality Assurance for Brachytherapy Imaging## 1. Required Phantom Tests### Geometric Accuracy Phantom| Test | Frequency | Tolerance | Method ||------|-----------|-----------|--------|| 3D geometric accuracy | Daily/Weekly | ≤2 mm | Image geometric grid phantom, measure known distances || Slice position accuracy | Weekly | ≤1 mm | Slice profile phantom || Slice thickness accuracy | Monthly | ≤1 mm | NIST-traceable thickness phantom |### Image Quality Phantoms- **American College of Radiology (ACR) MRI phantom**: Full protocol monthly- **Signal-to-noise ratio (SNR)**: Weekly minimum- **Ghosting ratio**: Weekly- **Spatial uniformity**: Weekly- **High-contrast spatial...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0856](../screenshots/02_Q0856.png)

---

### ✅ Q0857

**Input:** Explain how dynamic contrast-enhanced MRI (DCE-MRI) can improve assessment of treatment response during a course of brachytherapy. What pharmacokinetic parameters are measured, how do they correlate with tumor biology, and how can this information guide adaptive treatment planning decisions?...

**Response:**
> ## Dynamic Contrast-Enhanced MRI (DCE-MRI) in Brachytherapy### Pharmacokinetic Parameters MeasuredDCE-MRI analyzes contrast agent kinetics using the **Tofts model** or similar compartment models:| Parameter | Definition | Clinical Significance ||-----------|------------|----------------------|| **K^trans** | Volume transfer constant (plasma to EES) | Reflects vessel permeability and blood flow || **V_e** | Extravascular extracellular volume fraction | Tissue cellularity indicator || **K_ep** | Rate constant (EES back to plasma) | = K^trans / V_e || **AUC** | Area under concentration curve | Overall perfusion/permeability || **T_1/2** | Signal enhancement half-time | Time to peak enhancement |### Correlation with Tumor Biology- **High K^trans**: Indicates leaky, disorganized tumor vasculature — correlates with hypoxia- **Low V_e**: Suggests high cellular density (common in poorly differentiated tumors)- **Early...

**Scores:**
- Total: 0.86
- Keyword: 0.60
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0857](../screenshots/02_Q0857.png)

---

### ✅ Q0858

**Input:** Describe the imaging considerations for brachytherapy of head and neck tumors. How does the complex anatomy of the head and neck affect imaging protocols? What are the specific MRI sequences needed for different tumor subsites (oral cavity, oropharynx, larynx), and how does the presence of dental hardware affect imaging quality?...

**Response:**
> # Imaging Considerations for Head and Neck Brachytherapy## Challenges of Head and Neck AnatomyThe complex, layered anatomy of the head and neck creates unique imaging challenges:- **Small critical structures** (nerves, vessels, salivary ducts) with narrow tolerance margins- **Multiple tissue interfaces** (air-bone, air-soft tissue) causing magnetic susceptibility effects- **Tumor often interdigitates** with normal structures, making delineation difficult- **Functional anatomy** (swallowing, speech muscles) must be preserved## MRI Sequences by Tumor Subsite### Oral Cavity (Floor of Mouth, Tongue, Buccal Mucosa)| Sequence | Purpose | Key Parameters ||----------|---------|----------------|| **T2-weighted fat-saturated** | Tumor extent, peritumoral edema | TR 3000-5000ms, TE 80...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0858](../screenshots/02_Q0858.png)

---

### ✅ Q0859

**Input:** Explain the use of CT perfusion imaging for assessing tumor perfusion changes during brachytherapy. How can perfusion parameters (blood flow, blood volume, mean transit time) be used to evaluate early treatment response? What are the technical challenges of performing CT perfusion in the pelvis during a course of brachytherapy?...

**Response:**
> ## CT Perfusion Imaging for Brachytherapy Treatment Response Assessment### OverviewCT perfusion (CTP) imaging measures tissue blood flow, blood volume, and vascular permeability—parameters that change as tumors respond to radiation therapy. In brachytherapy, perfusion imaging can provide early indicators of treatment response before anatomical changes become apparent on conventional imaging.### Key Perfusion Parameters| Parameter | Definition | Clinical Significance ||-----------|------------|----------------------|| **Blood Flow (BF)** | Volume of blood per unit tissue per minute (mL/100g/min) | Reflects tissue vascularity; typically decreases with effective treatment || **Blood Volume (BV)** | Total blood volume in tissue (mL/100g) | Indicates vessel density; reduced BV suggests vascular damage || **Mean Transit Time (MTT)** | Average time for blood to traverse tissue |...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0859](../screenshots/02_Q0859.png)

---

### ✅ Q0860

**Input:** Describe the image-guided adaptive brachytherapy (IGABT) workflow for cervical cancer. How is the adaptive plan created from MRI images, what decisions must be made at each fraction regarding plan adaptation versus replanning, and how do you document and verify the adaptive process? Include discussion of the GEC-ESTRO recommendations for IGABT....

**Response:**
> # Image-Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer## OverviewIGABT represents the standard of care for locally advanced cervical cancer brachytherapy. The GEC-ESTRO recommendations (Reports I-V) provide the framework for MRI-based adaptive planning.---## 1. Pre-Brachytherapy MRI**Timing**: After completion of EBRT (typically week 4-5 of chemoradiation)**Sequences**:| Sequence | Purpose | Key Parameters ||----------|---------|----------------|| T2-weighted sagittal | Uterus anatomy, applicator assessment | TR/TE optimized, 3mm slices || T2-weighted axial (perpendicular to tandem) | High-resolution tumor assessment | 3mm slices, no gap || T2-weighted coronal |...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0860](../screenshots/02_Q0860.png)

---

### ✅ Q0861

**Input:** Explain how artificial intelligence and deep learning are being applied to brachytherapy imaging tasks. What are the current applications of AI in auto-contouring, applicator reconstruction, and image registration for brachytherapy? What are the validation requirements and limitations of AI-assisted imaging in the clinical brachytherapy setting?...

**Response:**
> ## AI and Deep Learning in Brachytherapy Imaging### Current Applications**1. Auto-Contouring (Auto-Segmentation)**- **CNN-based organ segmentation**: U-Net, nnU-Net architectures trained on pelvic CT/MRI for bladder, rectum, sigmoid, prostate- **Target volume delineation**: GTV/CTV auto-contouring for cervical, prostate, and breast brachytherapy- **Multi-structure ensembles**: Simultaneous contouring of 20+ OARs with 80-90% Dice score accuracy- **Adaptive learning**: Models that improve with institution-specific data through fine-tuning**2. Applicator Reconstruction**- **Marker-based detection**: CNN models to identify dwell positions and source channels on CT/MRI- **3D applicator modeling**: Automatic identification of tandem, ring, ovoid, cylinder...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0861](../screenshots/02_Q0861.png)

---

### ✅ Q0862

**Input:** Describe the use of 4D-CT imaging for brachytherapy planning in tumors affected by respiratory motion. How does 4D-CT improve target volume definition compared to conventional CT? What are the specific challenges of 4D-CT in the pelvis, and how do you manage respiratory motion in upper abdominal brachytherapy?...

**Response:**
> ## 4D-CT Imaging for Brachytherapy Planning in Mobile Tumors### What is 4D-CT?4D-CT (four-dimensional computed tomography) captures volumetric imaging synchronized with the respiratory cycle, creating a series of 3D datasets at multiple respiratory phases (typically 10 phases from 0% to 90%). This temporal dimension allows visualization of tumor and organ motion throughout the breathing cycle.### How 4D-CT Improves Target Volume Definition**Conventional CT limitations:**- Captures a single "snapshot" at an arbitrary respiratory phase- Cannot distinguish between static anatomy and mobile structures- May misrepresent the true extent of moving tumors- Internal Target Volume (ITV) must be estimated or measured with alternative techniques**4D-CT advantages:**- **ITV directly measured**: The total tumor excursion envelope is visualized directly- **Phase-by-phase...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0862](../screenshots/02_Q0862.png)

---

### ✅ Q0863

**Input:** Explain the concept of MRI thermometry for brachytherapy applications. How can real-time temperature mapping during brachytherapy improve treatment delivery? What are the technical requirements for MRI thermometry, and what is the current evidence for its clinical utility in brachytherapy?...

**Response:**
> ## MRI Thermometry in Brachytherapy### ConceptMRI thermometry uses MRI signal changes to map temperature distributions in real-time during thermal therapies. While most established for focused ultrasound (MRgFUS), it has emerging applications in brachytherapy.### Key Mechanisms| Parameter | Technical Basis ||-----------|-----------------|| **Proton Resonance Frequency (PRF) Shift** | Primary method; temperature sensitivity ~0.01 ppm/°C in water protons || **T1 Relaxation Time** | Increases with temperature (~1% per °C) || **Apparent Diffusion Coefficient (ADC)** | Increases with temperature due to enhanced molecular diffusion |### Applications in Brachytherapy**1. Thermal Ablation Guidance...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0863](../screenshots/02_Q0863.png)

---

### ✅ Q0864

**Input:** Describe the imaging requirements for quality assurance of MRI-guided brachytherapy programs. What test objects and phantoms are needed, how do you verify imaging accuracy across the MRI room and treatment room, and what are the specific QA recommendations from professional organizations?...

**Response:**
> ## MRI-Guided Brachytherapy Quality Assurance: Imaging Requirements### 1. Essential Test Objects and Phantoms| Phantom Type | Purpose | Key Specifications ||--------------|---------|-------------------|| **Geometric accuracy phantom** | Verify MRI spatial accuracy | Grid of known markers (1–5 mm spacing), detectable in all sequences || **Distortion phantom** | Measure geometric distortion | Large field-of-view (≥50 cm), high-density marker grid || **Signal uniformity phantom** | Verify B1 homogeneity | Uniform gel or water-filled container || **Applicator compatibility phantom** | Test MR-compatible applicator visualization | Allow visualization of actual clinical applicators (tandem, ring, ovoids, interstitial needles) || **Coil-specific ph...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0864](../screenshots/02_Q0864.png)

---

### ✅ Q0865

**Input:** Explain how radiomics and texture analysis of pre-treatment MRI can predict brachytherapy outcomes in cervical cancer. What specific radiomic features correlate with local control and toxicity? How should radiomic studies be designed to ensure reproducibility and clinical applicability?...

**Response:**
> ## Radiomics and Texture Analysis for Cervical Cancer Brachytherapy Outcomes### OverviewRadiomics extracts quantitative features from medical images that capture tumor phenotypic characteristics invisible to the human eye. In cervical cancer brachytherapy, these features can predict treatment response and toxicity before treatment begins.---### Key Radiomic Feature Categories| Feature Category | Description | Clinical Relevance ||-----------------|-------------|-------------------|| **Shape features** | Sphericity, irregularity, compactness | Tumor morphology correlates with侵略性 || **First-order histogram** | Mean, std, entropy, skewness, kurtosis | Reflects tissue heterogeneity || **Texture matrices** | GLCM, GLRLM, GLSZM, NGTDM | Quantifies spatial heterogeneity || **Higher-order statistics** | Fractal dimension, Laplacian features | Captures complex patterns |---### Features Predicting Local Control**Favorable Prognosis Indicators:**- **Low entropy...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0865](../screenshots/02_Q0865.png)

---

### ✅ Q0866

**Input:** Describe the use of multiparametric MRI (mpMRI) for brachytherapy planning in prostate cancer. How do T2-weighted, DW-MRI, and DCE-MRI sequences complement each other for target delineation? What is the evidence for MRI-based prostate brachytherapy planning compared to TRUS and CT?...

**Response:**
> ## Multiparametric MRI for Prostate Brachytherapy Planning### Core mpMRI Sequences**1. T2-Weighted Imaging (T2WI)**- **Primary sequence**: Excellent anatomical delineation of the prostate gland, transition zone, and peripheral zone- **Use**: Defines prostate boundaries, identifies extracapsular extension (ECE), evaluates seminal vesicle involvement- **Limitations**: Cannot reliably distinguish tumor from normal tissue within the same zone**2. Diffusion-Weighted Imaging (DWI)**- **Primary sequence**: Detects restricted diffusion characteristic of high cellularity tumors- **Use**: Identifies suspicious lesions within the prostate, particularly in the peripheral zone- **Apparent Diffusion Coefficient (ADC)**: Low ADC correlates with higher Gleason grade; ADC maps help target biopsy-positive regions- **b-values**: Typically use...

**Scores:**
- Total: 0.80
- Keyword: 0.43
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0866](../screenshots/02_Q0866.png)

---

### ✅ Q0867

**Input:** Explain how cone-beam CT (CBCT) with dual-energy capabilities can improve brachytherapy planning and verification. What are the advantages of dual-energy CBCT for tissue characterization, metal artifact reduction, and applicator visualization in brachytherapy?...

**Response:**
> ## Dual-Energy Cone-Beam CT (DE-CBCT) for Brachytherapy### OverviewDual-energy CBCT acquires images at two different x-ray energy spectra, enabling material-specific imaging that overcomes limitations of conventional single-energy CBCT.### Advantages for Brachytherapy#### 1. **Tissue Characterization**- Separates materials based on atomic number (Z) and electron density- Distinguishes between soft tissue, fat, bone, and contrast agents- Improves tumor visualization against normal tissues- Quantifies iodine concentration in contrast-enhanced studies#### 2. **Metal Artifact Reduction**- Significantly reduces streak artifacts from high-Z brachytherapy applicators (titanium, stainless steel)- Enables accurate visualization of applicator geometry near metal- Improves dose calculation accuracy in presence of applicators- Particularly valuable for tandem/...

**Scores:**
- Total: 0.86
- Keyword: 0.60
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0867](../screenshots/02_Q0867.png)

---

### ✅ Q0995

**Input:** A center is developing a protocol for using synthetic CT generation from MRI for dose calculation in MRI-guided brachytherapy. Describe the sCT generation methodology, the validation requirements for dose calculation accuracy compared to conventional CT, the specific challenges of sCT generation near metallic applicators, and the regulatory pathway for clinical implementation of MRI-only treatment planning....

**Response:**
> # Synthetic CT Generation for MRI-Guided Brachytherapy## OverviewSynthetic CT (sCT) generation enables MRI-only treatment planning by converting MRI images into CT-like data for dose calculation. This eliminates the need for conventional CT simulation while maintaining dosimetric accuracy.---## 1. sCT Generation Methodology### Primary Approaches| Method | Description | Advantages | Limitations ||--------|-------------|------------|-------------|| **Atlas-based** | Deformably register MRI to CT atlas, propagate HU values | Robust for normal anatomy | Fails near artifacts/pathology || **Voxel-based/ML** | Train model (random forest, CNN) on MRI→CT pairs | Patient-specific, handles pathology | Requires large training dataset || **Hybrid** | Combine atlas registration with ML refinement | Balances robustness and accuracy...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0995](../screenshots/02_Q0995.png)

---

### ✅ Q1711

**Input:** I need to understand how MRI-guided adaptive brachytherapy (IGABT) works for cervical cancer. Specifically: (1) What imaging sequences are recommended for brachytherapy planning MRI, (2) How does MRI improve target volume delineation compared to CT, (3) What is the concept of adaptive treatment planning in brachytherapy, and (4) How does the GEC-ESTRO recommends reporting MRI-based brachytherapy plans?...

**Response:**
> ## MRI-Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer### 1. Recommended MRI Sequences for Brachytherapy Planning**Essential Sequences:**| Sequence | Purpose | Key Parameters ||----------|---------|-----------------|| **T2-weighted (T2W)** | Primary for soft tissue visualization, GTV/CTV delineation | High-resolution, small FOV, TSE/FSE || **T1-weighted (T1W)** | Anatomy reference, capsule assessment | With and without fat suppression || **Diffusion-weighted (DWI)** | Tumor viability, treatment response assessment | b-values 0, 500, 1000 s/mm² || **Dynamic Contrast-Enhanced (DCE)** | Perfusion, tumor biology | Temporal resolution <5 seconds |**Field Strength Considerations:**-...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1711](../screenshots/02_Q1711.png)

---

### ✅ Q1712

**Input:** I am performing CT-MRI fusion for prostate brachytherapy planning. The patient has a pelvic MRI with T2-weighted sequences. I need to understand: (1) What are the recommended MRI sequences for prostate delineation, (2) How do I perform CT-MRI registration and what are the sources of registration error, (3) How does MRI improve prostate and OAR delineation compared to CT, and (4) What quality assurance steps should I perform for the fused images?...

**Response:**
> ## CT-MRI Fusion for Prostate Brachytherapy Planning### 1. Recommended MRI Sequences for Prostate Delineation**Multiparametric MRI (mpMRI) Protocol:**| Sequence | Purpose | Key Parameters ||---------|--------|----------------|| **T2-weighted (T2w)** | Primary for prostate capsule, zonal anatomy, NVB | Turbo spin echo, high resolution, small FOV || **Diffusion-weighted (DWI)** | Tumor detection (PI-RADS scoring) | b-values 50-100, 400-800, 1400-2000 s/mm² || **Dynamic Contrast-Enhanced (DCE)** | Tumor vascularity, treatment response | Temporal resolution <5 seconds || **Magnetic Resonance Spectroscopic Imaging (MRSI)** | Metabolic assessment (optional) | Choline/c...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1712](../screenshots/02_Q1712.png)

---

### ✅ Q1713

**Input:** I need to understand the concept of deformable image registration (DIR) for adaptive brachytherapy. In cervical cancer IGABT, the applicator position and tumor shape change between fractions. How does DIR help accumulate dose across fractions? What are the available DIR algorithms (B-spline, demons, etc.)? What are the limitations and accuracy of DIR in the pelvis? How should I validate DIR results for brachytherapy applications?...

**Response:**
> # Deformable Image Registration (DIR) for Adaptive Brachytherapy## Role of DIR in Dose Accumulation**Why DIR is needed:**In cervical cancer IGABT, significant anatomical changes occur between fractions due to:- Tumor regression (20-60% volume reduction)- Applicator repositioning- Bladder/rectal filling variations- Weight changesDIR maps doses from each fraction onto a common reference frame, enabling accurate cumulative dose calculation.### Dose Accumulation Workflow```Fraction 1 CT/MRI → Contours + Dose → DIR to ReferenceFraction 2 CT/MRI → Contours + Dose → DIR to Reference  Fraction 3 CT/MRI → Contours + Dose → DIR to ReferenceFraction 4 CT/MRI → Contours + Dose → DIR to Reference                                         ↓                              Cumulative Dose-Volume Histogram```**Key applications:**- Calculate cumulative EQD2 to OARs (rect...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1713](../screenshots/02_Q1713.png)

---

### ✅ Q1714

**Input:** I am evaluating PET-CT for brachytherapy planning in cervical cancer. FDG-PET can visualize the primary tumor and lymph nodes. How should I integrate PET findings into brachytherapy target volume delineation? What are the limitations of PET for brachytherapy planning? How does PET-CT compare with MRI for target delineation? Should I use PET-CT routinely for brachytherapy planning?...

**Response:**
> ## PET-CT for Cervical Cancer Brachytherapy Planning### Integration of PET Findings into Target Volume Delineation**Role of FDG-PET in GTV Definition:**- PET provides metabolic information that complements anatomical imaging- The FDG-avid region represents metabolically active tumor tissue- PET can help identify residual disease after EBRT that may not be visible on CT/MRI- Standard uptake value (SUV) measurements correlate with tumor aggressiveness**Practical Integration Approach:**1. **GTV-PET** = FDG-avid region on PET-CT2. Fuse PET-CT with planning MRI/CT for applicator reconstruction3. Use PET to guide GTV delineation, but contour on the fused MRI/CT for precision4. PET is most useful for:   - Identifying involved lymph nodes   - Detecting disease in areas difficult to assess on MRI (e.g., parametrial extension near pelvic side...

**Scores:**
- Total: 0.85
- Keyword: 0.57
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1714](../screenshots/02_Q1714.png)

---

### ✅ Q1715

**Input:** I need to understand how to perform MRI-based brachytherapy planning for cervical cancer using the T2-weighted sequences. The GEC-ESTRO recommends delineating: HR-CTV, IR-CTV, and the OARs. How do I delineate the HR-CTV on axial T2-weighted images? What are the specific boundaries? How do I account for the applicator in MRI-based planning? What is the recommended MRI protocol for brachytherapy?...

**Response:**
> # MRI-Based Brachytherapy Planning for Cervical Cancer## 1. Recommended MRI Protocol### Pre-Insertion MRI (without applicator)| Sequence | Slice Thickness | Purpose ||----------|----------------|---------|| **T2-weighted sagittal** | 3 mm | Initial tumor assessment, anatomy overview || **T2-weighted axial (small FOV)** | 3 mm | HR-CTV, IR-CTV delineation || **T2-weighted coronal** | 3 mm | Parametrial extension, vagina || **T1-weighted axial** | 4-5 mm | Lymph node assessment || **DWI (b-values 0, 500, 1000)** | 4 mm | Tumor viability, lymph nodes |### Post-Insertion MRI (with applicator in place)| Sequence | Slice Thickness | Requirements ||----------|----------------|--------------|| **T2-weighted axial/perpendicular to tandem** |...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1715](../screenshots/02_Q1715.png)

---

### ✅ Q1716

**Input:** I am performing a quality assurance check on the CT simulation for brachytherapy planning. I need to verify: (1) CT number accuracy using a phantom, (2) geometric accuracy of the CT images, (3) the effect of contrast material on CT-based dose calculation, and (4) the appropriate CT-to-electron-density conversion table for brachytherapy applicators. How do I perform each of these QA checks?...

**Response:**
> # CT Simulation QA for Brachytherapy Planning## 1. CT Number Accuracy Verification**Purpose**: Ensure HU values correspond correctly to tissue densities**Procedure**:- Use a CT QA phantom (e.g., CatPhan, Gammex RMI 467)- Include materials with known HU values: water (0 HU), air (-1000 HU), bone (+300 to +1000 HU), polyethylene, acrylic, Delrin- Scan phantom using clinical brachytherapy protocol- Measure HU values in each region of interest- Compare measured vs. expected values**Acceptance Criteria**:- ±20 HU for water and soft tissue equivalent materials- ±40 HU for bone-mimicking materials- ±10...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1716](../screenshots/02_Q1716.png)

---

### ✅ Q1717

**Input:** I need to understand the concept of 4D brachytherapy planning. In cervical cancer IGABT, the tumor and applicator positions change between fractions. How does 4D brachytherapy account for these changes? What imaging should be performed at each fraction? How should I accumulate dose across fractions using deformable registration? What are the clinical benefits of 4D planning compared to single-fraction planning?...

**Response:**
> ## 4D Brachytherapy Planning in Cervical Cancer IGABT### What is 4D Brachytherapy?4D brachytherapy accounts for temporal changes in tumor position, shape, and applicator geometry across treatment fractions. Unlike static planning, it captures the "fourth dimension" of time.### Sources of Inter-Fraction Variation| Source | Magnitude | Clinical Impact ||--------|-----------|-----------------|| **Tumor shrinkage** | 30-50% volume reduction | HR-CTV changes shape dynamically || **Applicator migration** | 5-15 mm | Source positions shift relative to target || **Bladder filling** | ±50% volume change | Displaces uterus/applicator || **Rectal dist...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1717](../screenshots/02_Q1717.png)

---

### ✅ Q1718

**Input:** I am evaluating the use of ultrasound for real-time guidance during prostate brachytherapy seed implantation. How does transrectal ultrasound (TRUS) guidance work for prostate seed implantation? What are the advantages of real-time TRUS-guided implantation compared to pre-planned approaches? How do I perform prostate volume reconstruction from TRUS images? What are the limitations of TRUS for prostate delineation?...

**Response:**
> ## Transrectal Ultrasound (TRUS) Guidance for Prostate Brachytherapy### How TRUS Guidance Works**Real-time Imaging During Implantation:**- TRUS probe (typically 6-10 MHz) inserted transrectally provides sagittal and axial images- Prostate boundaries visualized in real-time as needles are advanced- Seed deployment monitored under direct visualization- Typical approach: **Modified Stamford technique** with sagittal guidance**Workflow:**1. Pre-operative TRUS to obtain prostate volume and dimensions2. Systematic grid-based needle placement (5 mm spacing)3. Real-time verification of needle tip position relative to prostate capsule4. Seed deployment with visual confirmation5. Post-implant TRUS to verify seed placement---### Advantages of Real-Time TRUS vs. Pre...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1718](../screenshots/02_Q1718.png)

---

### ✅ Q1719

**Input:** I need to understand the role of diffusion-weighted MRI (DW-MRI) in brachytherapy planning for cervical cancer. How does DW-MRI help in tumor delineation? What is the apparent diffusion coefficient (ADC) and how does it relate to tumor biology? Can DW-MRI help predict treatment response during brachytherapy? What are the limitations of DW-MRI for brachytherapy target delineation?...

**Response:**
> ## Diffusion-Weighted MRI (DW-MRI) in Cervical Cancer Brachytherapy Planning### 1. How DW-MRI Improves Tumor DelineationDW-MRI is a functional imaging technique that detects the random motion of water molecules in tissues. Unlike T2-weighted MRI, which shows anatomical structures, DW-MRI provides **biological information** about tissue cellularity and membrane integrity.**For cervical cancer target delineation:**| Feature | Clinical Application ||---------|---------------------|| **High signal on high-b-value images** | Restricted diffusion in tumors helps distinguish malignant tissue from normal cervix/stroma || **Low ADC values** | Reflects high cellularity typical of viable tumor || **Signal void on ADC maps** | Helps identify necrotic regions (high ADC) that should be excluded from...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1719](../screenshots/02_Q1719.png)

---

### ✅ Q1720

**Input:** I am performing a brachytherapy planning quality assurance review. I need to verify the accuracy of the CT-based applicator reconstruction. How do I verify that the applicator reconstruction on CT is geometrically accurate? What are the potential sources of reconstruction error? How does applicator reconstruction accuracy affect dose calculation? What QA tools exist for applicator reconstruction verification?...

**Response:**
> ## CT-Based Applicator Reconstruction QA### Verification Methods**1. Radiopaque Marker Wire Method**- Insert a radiopaque wire through the entire applicator channel before CT scan- Acquire CT with identical protocol used for treatment planning- Verify the reconstructed length matches the known physical applicator length- **Acceptance criteria**: ±1 mm deviation**2. Cone-Beam CT with Integrated Markers**- Many modern applicators have integrated fiducial markers visible on CT- Verify marker positions match expected geometry from manufacturer specifications**3. Anthropomorphic Phantom Testing**- Scan applicators in a pelvic phantom with known geometry- Compare reconstructed positions to known truth- Use dedicated brachytherapy QA phantoms (e.g., Proctur, CIRS)**4. Independent Verification**...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1720](../screenshots/02_Q1720.png)

---

### ✅ Q1721

**Input:** I need to understand how cone-beam CT (CBCT) can be used for brachytherapy guidance. What are the advantages of CBCT over conventional CT for brachytherapy? How does CBCT image quality compare to CT for applicator and target visualization? What are the radiation dose implications of using CBCT for brachytherapy guidance? Should I use CBCT routinely for brachytherapy fraction imaging?...

**Response:**
> ## Cone-Beam CT (CBCT) for Brachytherapy Guidance### Advantages of CBCT over Conventional CT for Brachytherapy| Feature | CBCT | Conventional CT ||---------|------|-----------------|| **Portability** | Can be mounted on linac or C-arm | Fixed scanner, requires patient transport || **In-room guidance** | Performed with patient in treatment position | Separate imaging suite || **Soft tissue contrast** | Limited without contrast | Superior native soft tissue resolution || **Acquisition time** | 30-60 seconds | 5-10 seconds || **Dose per scan** | 2-6 cGy | 3-7 cGy || **Applicator visualization** | Good for high-contrast materials | Excellent |### Key Advantages for Brachytherapy1. **Same-day imaging and treatment...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1721](../screenshots/02_Q1721.png)

---

### ✅ Q1722

**Input:** I am evaluating the use of MRI for post-implant dosimetry evaluation of prostate LDR brachytherapy. How does MRI improve seed visualization compared to CT? What MRI sequences are best for seed localization? How does MRI-based post-implant dosimetry compare with CT-based evaluation? What are the practical challenges of MRI-based post-implant dosimetry?...

**Response:**
> ## MRI-Based Post-Implant Dosimetry for Prostate LDR Brachytherapy### How MRI Improves Seed Visualization Compared to CT| Feature | CT | MRI ||---------|-----|-----|| **Seed visibility** | Excellent for seed localization | Variable; depends on seed composition and sequence || **Soft tissue contrast** | Limited | Superior for prostate capsule, neurovascular bundles || **Prostate boundaries** | Often unclear | Clearly delineated on T2W || **Artifacts** | Beam hardening from seeds | Susceptibility artifacts (can aid seed identification) |**CT limitations**: Seeds cause beam hardening artifacts; prostate-gland interface often indistinct; difficult to visualize extraprostatic seed placement.**MRI advantages**: Direct visualization of prostate anatomy; seeds visible as signal voids on most sequences; can identify periprostatic spread and extraprostatic seeds.---### Recommended MRI Sequences for Seed...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1722](../screenshots/02_Q1722.png)

---

### ✅ Q1723

**Input:** I need to understand how to handle MRI artifacts in brachytherapy planning. What types of MRI artifacts can affect brachytherapy planning (susceptibility artifacts from metallic applicators, chemical shift artifacts, motion artifacts)? How do these artifacts affect target and applicator delineation? What correction methods exist? How should I adjust the MRI protocol to minimize artifacts?...

**Response:**
> # MRI Artifacts in Brachytherapy Planning## Types of MRI Artifacts### 1. Susceptibility Artifacts (Metallic Applicators)**Cause**: Magnetic field inhomogeneity from MR-compatible metal alloys (titanium, aluminum, certain stainless steels)**Clinical Impact**:- Signal void around applicator tip (10-20 mm depending on field strength)- Distortion of applicator geometry- Difficulty visualizing OARs immediately adjacent to applicator- May obscure critical structures like bladder wall, rectal wall**Mitigation**:- Use spin echo sequences (less susceptible than gradient echo)- Increase bandwidth (reduces chemical shift and susceptibility)- Reduce echo time (TE)- Use titanium applicators (lower susceptibility than steel)- **Image fusion with CT** for applicator localization (gold standard for geometry)### 2. Chemical Shift Artifacts**Cause...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1723](../screenshots/02_Q1723.png)

---

### ✅ Q1724

**Input:** I am implementing an image-guided adaptive brachytherapy (IGABT) program for cervical cancer. What imaging equipment and software are needed? What is the recommended imaging protocol (CT, MRI, or both)? How do I integrate imaging into the brachytherapy workflow? What are the staffing and training requirements for an IGABT program? What are the cost considerations?...

**Response:**
> # Implementing an Image-Guided Adaptive Brachytherapy (IGABT) Program for Cervical Cancer## 1. Imaging Equipment and Software Requirements### Primary Imaging Modalities| Equipment | Purpose | Specifications ||-----------|---------|----------------|| **1.5T MRI Scanner** | Primary for soft tissue visualization, target delineation | Minimum requirement; 3T preferred for research || **CT Simulator** | Applicator reconstruction, dose calculation | Flat table top, wide bore (≥80 cm) || **CBCT (optional)** | Daily verification, soft tissue matching | Integrated with treatment delivery system || **Ultrasound (TRUS)** | Applicator guidance, brachytherapy suite use | High-frequency endocavitary probe |### Software Requirements| Software | Function | Examples ||----------|----------|----------|| **MRI-TPS Integration** | Image import,...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1724](../screenshots/02_Q1724.png)

---

### ✅ Q1725

**Input:** I need to understand the concept of functional imaging for brachytherapy planning. How can DCE-MRI help in target delineation for cervical cancer brachytherapy? What pharmacokinetic parameters (Ktrans, Ve, Vp) are relevant? Can functional imaging help predict brachytherapy response? What are the limitations of functional imaging for brachytherapy planning?...

**Response:**
> ## DCE-MRI for Cervical Cancer Brachytherapy Planning### How DCE-MRI Improves Target DelineationDCE-MRI visualizes tumor vascularity through dynamic contrast enhancement patterns:| Finding | Clinical Significance ||---------|---------------------|| **Early enhancement** | Indicates high perfusion, often corresponds to viable tumor || **Delayed washout** | Suggests aggressive tumor biology || **Heterogeneous enhancement** | May indicate areas of hypoxia or necrosis |**GEC-ESTRO recommendation**: T2-weighted MRI remains the primary sequence for HR-CTV delineation. DCE-MRI is complementary, not primary.---### Pharmacokinetic Parameters| Parameter | Definition | Clinical Meaning ||-----------|------------|------------------|| **K^trans** (volume transfer constant) | Rate of contrast transfer from plasma to EES | Permeability; elevated in active tumor || **V_e** (extravascular extracellular volume) | Volume fraction of EES | Tissue cellularity;...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1725](../screenshots/02_Q1725.png)

---

### ✅ Q1726

**Input:** I am performing brachytherapy planning for a breast cancer patient using multi-catheter interstitial applicator. I need to understand: (1) What imaging modality is best for catheter reconstruction, (2) How do I verify catheter positions using CT, (3) What is the role of 3D printing for customized applicators, and (4) How do I perform CT-based dose optimization for the multi-catheter plan?...

**Response:**
> # Multi-Catheter Interstitial Brachytherapy for Breast Cancer: Planning Workflow## 1. Imaging Modality for Catheter Reconstruction**CT is the preferred primary imaging modality** for catheter reconstruction in breast brachytherapy:| Modality | Advantages | Limitations ||----------|-----------|-------------|| **CT** | Excellent visualization of catheters with contrast; reproducible; standardized HU for digitization | Soft tissue contrast limited; catheter tip visibility varies || **MRI** | Superior soft tissue; excellent for tumor delineation | Catheter artifacts; longer acquisition; less available || **TRUS** | Real-time guidance; good for superficial lesions | Limited depth penetration; operator-dependent |**Recommended approach**: CT simulation (1-2 mm slice thickness) with radiopaque markers at catheter tips. Some centers use...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1726](../screenshots/02_Q1726.png)

---

### ✅ Q1727

**Input:** I need to understand the concept of MRI thermometry for brachytherapy guidance. Can MRI thermometry be used to monitor tissue temperature during HDR brachytherapy? How does MRI thermometry work? What are the applications of MRI thermometry in brachytherapy? What are the limitations of current MRI thermometry technology?...

**Response:**
> ## MRI Thermometry for Brachytherapy Guidance### How MRI Thermometry WorksMRI thermometry uses the temperature dependence of MRI parameters to create real-time temperature maps:| Parameter | Temperature Coefficient | Mechanism ||-----------|----------------------|-----------|| **Proton Resonance Frequency (PRF)** | -0.01 ppm/°C | Primary method; shift in water resonance frequency || **T1 Relaxation Time** | +1-2%/°C | Sensitive but less accurate || **Diffusion Coefficient (ADC)** | +2-3%/°C | Temperature-dependent molecular motion || **MRS Spectroscopy** | Chemical shift changes | Direct measurement of temperature-sensitive metabolites |**PRF-shift method** is most commonly used for its linear relationship with temperature and relative insensitivity to tissue type changes.---### Clinical Applications in Brachytherapy**Primary Application: MR-guided Hyperthermia Combined with Brachytherapy**- Temperature monitoring during interstitial hyperthermia delivered concurrently with brachythera...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1727](../screenshots/02_Q1727.png)

---

### ❌ Q1728

**Input:** I am evaluating the use of artificial intelligence (AI) for brachytherapy planning. How can AI assist in: (1) automatic applicator reconstruction from CT/MRI, (2) automatic target volume delineation, (3) dose optimization, and (4) plan quality evaluation? What are the current limitations of AI in brachytherapy? What validation studies exist for AI-based brachytherapy planning?...

**Response:**
> # AI in Brachytherapy Planning## 1. Automatic Applicator Reconstruction**Methods:**- **CNN-based segmentation** (U-Net, ResNet architectures) trained on CT/MRI datasets to identify applicator markers and catheters- **3D reconstruction** from 2D fluoroscopy or sparse CT slices using deep learning- **Marker detection algorithms** for tandem, ring, ovoid, and interstitial needle identification**Current State:**- Commercial solutions exist (e.g., Oncentra Brachy, Variseed) with semi-automatic reconstruction- Fully automatic reconstruction still requires physicist verification- Accuracy typically 1-2 mm for metallic markers---## 2. Automatic Target Volume Delineation**Methods:**- **Atlas-based...

**Scores:**
- Total: 0.71
- Keyword: 0.17
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1728](../screenshots/02_Q1728.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1729

**Input:** I need to understand the role of PET-MRI for brachytherapy planning. What are the advantages of combined PET-MRI over sequential PET-CT and MRI? How does simultaneous PET-MRI acquisition improve target delineation? What are the technical challenges of PET-MRI for brachytherapy? Is PET-MRI clinically superior to PET-CT plus MRI for brachytherapy planning?...

**Response:**
> ## PET-MRI in Brachytherapy Planning### Advantages of Combined PET-MRI Over Sequential PET-CT + MRI**1. Temporal Co-registration**- Simultaneous acquisition eliminates inter-modality misregistration from patient movement, respiration, or organ filling changes- Prostate, cervix, and pelvic organs are subject to positional variation between separate scans (can be 5-15 mm)- Eliminates need for deformable image registration between separate datasets**2. Soft Tissue Characterization**- MRI provides superior soft tissue contrast for gross tumor volume (GTV) delineation- PET provides metabolic/biological information (FDG avidity, hypoxia markers)- Combined functional and anatomical imaging in one session**3. Reduced Radiation...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1729](../screenshots/02_Q1729.png)

---

### ✅ Q1730

**Input:** I am performing a brachytherapy planning review for a cervical cancer patient. The planning CT shows significant motion artifact in the pelvic region due to bowel peristalsis. How does motion artifact affect brachytherapy dose calculation? What are the strategies to minimize motion artifact during CT simulation? Should I repeat the CT scan? How does motion artifact affect applicator reconstruction accuracy?...

**Response:**
> ## Motion Artifact in Cervical Cancer Brachytherapy CT Planning### Impact on Dose Calculation**Applicator position uncertainty:**- Bowel peristalsis can shift the tandem/ovoid position by **2-5 mm** between CT slices- This introduces dwell position uncertainty that propagates to dose distribution- The dose may be delivered to different tissue than planned**Organ-at-risk contours:**- Bladder and rectal filling changes between planning and treatment- Motion artifact makes OAR delineation uncertain (±3-5 mm)- D2cc, D1cc metrics may be unreliable**Dose-volume histogram impact:**- Target...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1730](../screenshots/02_Q1730.png)

---

### ✅ Q1731

**Input:** I need to understand how dual-energy CT (DECT) can be used for brachytherapy planning. What are the advantages of DECT over single-energy CT for applicator and tissue delineation? How does DECT improve material decomposition? Can DECT reduce metallic artifacts from brachytherapy applicators? What are the clinical applications of DECT in brachytherapy?...

**Response:**
> ## Dual-Energy CT (DECT) for Brachytherapy Planning### Advantages Over Single-Energy CT| Feature | Single-Energy CT | Dual-Energy CT ||---------|------------------|----------------|| Material differentiation | Limited HU-based | Explicit material decomposition || Tissue characterization | Bulk density | Iodine/water/calcium separation || Artifact reduction | Basic interpolation | Virtual monochromatic imaging || Applicator visualization | Standard | Metal artifact reduction modes |### Material DecompositionDECT acquires data at two energy levels (typically 80/100 kVp and 140 kVp), enabling:- **Iodine density maps**: Separate contrast enhancement from soft tissue- **Virtual non-contrast (VNC)**: Assess native tissue without contrast bolus- **Effective atomic number mapping**: Differentiate tissue types based on composition### Metal Artifact ReductionFor brachytherapy with...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1731](../screenshots/02_Q1731.png)

---

### ✅ Q1732

**Input:** I am implementing MRI-guided brachytherapy for prostate cancer. I need to understand: (1) What MRI sequences are recommended for prostate delineation during brachytherapy, (2) How do I perform MRI-based applicator reconstruction, (3) What are the differences between MRI-based and CT-based dose calculations for prostate brachytherapy, and (4) What QA procedures should I perform for MRI-guided prostate brachytherapy?...

**Response:**
> ## MRI-Guided Brachytherapy for Prostate Cancer: Implementation Guide### 1. Recommended MRI Sequences for Prostate Delineation**Primary Sequences:**| Sequence | Purpose | Parameters ||----------|---------|------------|| **T2-weighted (T2W)** | Primary anatomical delineation | Axial + sagittal, 3mm slice, high resolution || **Diffusion-weighted (DWI)** | Cancer detection, PIRADS scoring | b-values: 0, 500, 1000, 1400 s/mm² || **Dynamic Contrast-Enhanced (DCE)** | Vascularity, cancer localization | Temporal resolution <10 seconds |**Supplementary Sequences:**- T1-weighted with fat saturation (for bleeding/hematoma)- Apparent Diffusion...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1732](../screenshots/02_Q1732.png)

---

### ✅ Q1733

**Input:** I need to understand the concept of radiomics and texture analysis for brachytherapy planning. How can radiomics features extracted from MRI help predict brachytherapy response? What texture features are most relevant for cervical cancer brachytherapy? How can machine learning models be trained to predict treatment outcomes? What are the limitations of radiomics for brachytherapy?...

**Response:**
> # Radiomics and Texture Analysis in Brachytherapy Planning## OverviewRadiomics involves extracting quantitative features from medical images to characterize tumor phenotype and predict treatment response. In brachytherapy, these features can be extracted from MRI (T2-weighted, DWI, DCE) to guide treatment planning and predict outcomes.## Key Texture Features for Cervical Cancer| Feature Category | Examples | Clinical Relevance ||------------------|----------|-------------------|| **First-order statistics** | Mean, SD, skewness, kurtosis | Overall signal intensity distribution || **Shape-based** | sphericity, compactness | Tumor morphology || **Histogram-based** | entropy, uniformity | Heterogeneity quantification || **Texture matrices** | GLCM (contrast, dissimilarity), GLRLM, GLSZM | Spatial arrangement of intensities |## Relevant Texture Features for Cervical Brachytherapy- **Entropy and uniformity**: Higher entropy...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1733](../screenshots/02_Q1733.png)

---

### ✅ Q1734

**Input:** I am performing quality assurance on the MRI scanner used for brachytherapy planning. What specific QA tests should I perform? How do I verify MRI geometric accuracy? How do I ensure consistent image quality over time? What are the recommended QA frequencies for MRI in radiation oncology?...

**Response:**
> ## MRI Quality Assurance for Brachytherapy Planning### Essential QA Tests| Test | Frequency | Tolerance ||------|-----------|-----------|| **Geometric Accuracy** | Daily/Monthly | ±1 mm || **Image Uniformity** | Monthly | Within manufacturer spec || **Signal-to-Noise Ratio (SNR)** | Monthly | Baseline ±10% || **Slice Thickness Accuracy** | Monthly | ±1 mm || **Slice Position Accuracy** | Monthly | ±1 mm || **High-Contrast Spatial Resolution** | Monthly | Meet specification || **Geometric Distortion (Large FOV)** | Annual | <2 mm at 20cm FOV |### Geometric Accuracy Testing**Daily QA:**- Electronic portal imaging device (EPID) or in-room QA camera for patient positioning**Monthly QA (AAPM TG 284 / ESTRO recommendations):**1...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1734](../screenshots/02_Q1734.png)

---

### ✅ Q1735

**Input:** I need to understand how to handle imaging data from multiple modalities in brachytherapy planning. For a cervical cancer patient, I have: (1) diagnostic MRI from initial staging, (2) treatment planning CT with applicator in place, (3) fraction-specific MRI with applicator, and (4) PET-CT from restaging. How do I integrate all these imaging datasets? What registration methods should I use? How do I account for different image resolutions and contrasts?...

**Response:**
> # Multi-Modality Image Integration for Cervical Cancer Brachytherapy Planning## Integration Workflow Overview### Step 1: Establish Reference ImageThe **treatment planning CT with applicator in place** should serve as the primary reference image because:- CT provides accurate geometric data for dose calculation- CT artifacts are minimal for dose computation- Applicator position is directly visualized on CT### Step 2: Registration Strategy by Dataset| Dataset | Registration Method | Purpose ||---------|---------------------|---------|| Diagnostic MRI → Planning CT | **Deformable** | Historical...

**Scores:**
- Total: 0.90
- Keyword: 0.71
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1735](../screenshots/02_Q1735.png)

---

### ✅ Q1736

**Input:** I am evaluating the use of MRI for brachytherapy planning in rectal cancer. How does MRI help in delineating the rectal tumor and mesorectal fascia? What MRI sequences are recommended for rectal cancer brachytherapy? How does MRI-based planning compare with CT-based planning for rectal brachytherapy? What are the challenges of MRI-guided rectal brachytherapy?...

**Response:**
> # MRI for Brachytherapy Planning in Rectal Cancer## Role of MRI in Rectal Tumor and Mesorectal Fascia DelineationMRI provides superior soft tissue contrast compared to CT, which is particularly important for rectal cancer where the target volume includes the tumor bed and potential areas of microscopic spread.**Tumor Visualization:**- High-resolution T2-weighted imaging clearly shows the rectal wall layers (mucosa, submucosa, muscularis propria, mesorectum)- Tumor invasion depth (T-stage) can be assessed with high accuracy- Mucinous adenocarcinomas show characteristic high T2 signal- Post-treatment fibrosis vs. residual tumor can be differentiated using MRI**Mesorectal Fascia (MRF) Assessment:**- The MRF appears as a thin hypointense layer on T2-weighted images- MRI accurately identifies MRF involvement (<1 mm from tumor)- Critical for planning as...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1736](../screenshots/02_Q1736.png)

---

### ✅ Q1737

**Input:** I need to understand the concept of virtual reality (VR) and 3D visualization for brachytherapy planning. How can 3D visualization improve brachytherapy treatment planning? What VR tools exist for radiation therapy planning? How does 3D visualization help with applicator placement assessment and dose evaluation? What are the limitations of current VR technology for brachytherapy?...

**Response:**
> ## Virtual Reality and 3D Visualization in Brachytherapy Planning### How 3D Visualization Improves Brachytherapy Planning**Dose Distribution Visualization**- 3D isodose surfaces allow intuitive understanding of dose falloff around applicators- Color-washed dose distributions on DVH projections reveal coverage gaps- Volume-rendered anatomy with dose overlay helps identify underdosed regions**Applicator Assessment**- Visualize applicator geometry relative to target and OARs- Identify spatial relationships that 2D slices may miss- Assess needle trajectories for interstitial implants pre-operatively**Patient Communication**- 3D models help patients understand their treatment- Visual demonstration of dose distribution to critical structures### Available VR Tools| Tool | Application ||------|-------------|| **...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1737](../screenshots/02_Q1737.png)

---

### ✅ Q1738

**Input:** I am performing image fusion for brachytherapy planning of a vaginal cancer. I have a planning CT with vaginal cylinder in place and a diagnostic MRI. How do I perform CT-MRI fusion for this case? What are the specific challenges of fusing CT and MRI for vaginal brachytherapy? How does the applicator affect the fusion accuracy? What QA steps should I perform to verify the fusion?...

**Response:**
> # CT-MRI Image Fusion for Vaginal Cancer Brachytherapy Planning## 1. Fusion Workflow### Step 1: Data Preparation- **CT Dataset**: Planning CT with vaginal cylinder in place (typically 1-2mm slice thickness)- **MRI Dataset**: Diagnostic MRI, ideally with T2-weighted sequences- Both datasets should be imported into the treatment planning system (TPS)### Step 2: Initial Registration- **Rigid Registration** as the first step:  - Use bony anatomy (pubic symphysis, obturator foramina) as primary reference  - Align pelvic bones using auto-registration algorithms  - Manual fine-tuning may be needed for optimal alignment### Step 3: Applicator Alignment- Use the vaginal cylinder as a secondary...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1738](../screenshots/02_Q1738.png)

---

### ✅ Q1739

**Input:** I need to understand how perfusion MRI can help in brachytherapy planning. How does dynamic contrast-enhanced (DCE) MRI assess tumor vascularity? Can perfusion parameters predict brachytherapy response? How should I incorporate perfusion data into brachytherapy target delineation? What are the technical requirements for performing perfusion MRI for brachytherapy planning?...

**Response:**
> ## Perfusion MRI in Brachytherapy Planning### How DCE-MRI Assesses Tumor VascularityDynamic contrast-enhanced MRI uses rapid T1-weighted imaging during injection of a gadolinium-based contrast agent to capture contrast uptake and washout in tissues.**Temporal dynamics measured:**- **Initial enhancement** (first 60-90 seconds): reflects arterial inflow- **Peak enhancement**: maximum signal intensity- **Washout phase**: contrast leaving the tissue**Key pharmacokinetic parameters:**| Parameter | What it measures | Clinical significance ||-----------|------------------|----------------------|| **K^trans** | Volume transfer constant (plasma→extravascular space) | Vessel permeability, angiogenesis || **V_e** | Extravascular extracellular volume fraction | Tissue cellularity || **K_ep** | Rate constant (extravascular→plasma) | Contrast washout rate || **AUC** |...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1739](../screenshots/02_Q1739.png)

---

### ✅ Q1740

**Input:** I am evaluating the accuracy of 3D ultrasound for brachytherapy guidance in gynecologic cancer. How does 3D ultrasound compare with MRI for target delineation? What are the advantages of 3D ultrasound over 2D ultrasound? Can 3D ultrasound replace MRI for brachytherapy planning in resource-limited settings? What are the training requirements for 3D ultrasound-guided brachytherapy?...

**Response:**
> ## 3D Ultrasound for Gynecologic Brachytherapy Guidance### Comparison with MRI| Feature | 3D Ultrasound | MRI ||---------|---------------|-----|| **Soft tissue contrast** | Moderate | Excellent || **Tumor visualization** | Good for endocervical/endouterine | Superior for parametrial extension || **Applicator visualization** | Good (acoustic shadowing) | Excellent (multiplanar) || **Delineation accuracy** | User-dependent | Gold standard || **Cost** | Low | High || **Availability** | Widely available | Limited || **Scan time** | Minutes | 20-30 minutes |### Advantages of 3D over 2D Ultrasound- **Volumetric data acquisition**: Single sweep captures entire volume- **Multiplanar reconstruction**: Review in sagittal, coronal, transverse planes post-acquisition- **Improved reproducibility**: Reduces operator dependence- **Better tumor-uterus relationship**:...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1740](../screenshots/02_Q1740.png)

---

### ✅ Q1741

**Input:** I need to understand the concept of dose accumulation using deformable registration in adaptive brachytherapy. For a cervical cancer patient treated with 5 fractions of HDR brachytherapy, how do I accumulate dose from each fraction? What deformable registration algorithms are most appropriate? How do I handle the applicator displacement between fractions? What are the uncertainties in dose accumulation?...

**Response:**
> ## Dose Accumulation in Adaptive Brachytherapy for Cervical Cancer### 1. Dose Accumulation Workflow**Step 1: Acquire Fraction-Specific Images**Each brachytherapy fraction should have its own imaging with applicator in place:- CT or MRI at each fraction- Include relevant anatomy (uterus, cervix, OARs)- Document applicator configuration**Step 2: Create Fraction-Specific Plans**- Calculate dose distribution for each fraction on its respective image set- Generate DVH parameters for each fraction**Step 3: Deformable Image Registration (DIR)**Register each fraction's image to a reference (typically fraction 1 or the last fraction)**Step 4: Dose Warping**- Map dose from each fraction to the reference geometry using the deformation vector field (DVF)- Accumulate warped doses: D_acc...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1741](../screenshots/02_Q1741.png)

---

### ✅ Q1742

**Input:** I am performing brachytherapy planning for a prostate cancer patient with a hip replacement. The metallic hip implant causes significant CT artifacts. How do these artifacts affect: (1) prostate contouring, (2) seed localization, (3) dose calculation, and (4) organ-at-risk delineation? What strategies can I use to mitigate these artifacts? Should I use MRI instead of CT for planning?...

**Response:**
> ## Managing Hip Prosthesis Artifacts in Prostate Brachytherapy Planning### Impact of Metal Artifacts| Area | Effect ||------|--------|| **Prostate Contouring** | Streak artifacts obscure 15-30% of prostate volume, making inferior and posterior boundaries difficult to define || **Seed Localization** | Metallic scatter causes seed identification errors; seeds near artifacts may appear duplicated or mispositioned || **Dose Calculation** | HU values in artifact regions are unreliable, affecting TG-43 scatter calculations; typical error: 5-15% || **OAR Delineation** | Rectal and bladder contours near artifacts are poorly visualized |### Mitigation Strategies**1. CT-Based Approaches:**- **Metal artifact reduction (MAR) algorithms**...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1742](../screenshots/02_Q1742.png)

---

### ✅ Q1743

**Input:** I need to understand the role of artificial intelligence in automatic organ-at-risk delineation for brachytherapy. How accurate are current AI algorithms for OAR segmentation in the pelvis? What are the clinical requirements for AI-based OAR delineation? How should I validate AI-generated contours before using them in brachytherapy planning? What are the current limitations?...

**Response:**
> ## AI-Based Automatic Organ-At-Risk Delineation in Brachytherapy### Current AI Algorithm Performance in Pelvis**Published accuracy metrics (typical):**| Structure | Dice Similarity Coefficient | 95% Hausdorff Distance ||-----------|---------------------------|------------------------|| Bladder | 0.88-0.95 | 2-4 mm || Rectum | 0.85-0.92 | 2-5 mm || Prostate | 0.88-0.94 | 1.5-3 mm || Cervix | 0.78-0.88 | 3-6 mm || Femoral heads | 0.92-0.96 | 1-2 mm || Bowel loops | 0.65-0.78 | 4-8 mm |**Key algorithms:**- U-Net and 3D U-Net variants (nnU-Net) — current standard- Transformer-based architectures (Swin UNETR, TransUNet)- Hybrid CNN-...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1743](../screenshots/02_Q1743.png)

---

### ✅ Q1744

**Input:** I am evaluating the use of spectral CT for brachytherapy planning. How does spectral CT improve material characterization compared to conventional CT? Can spectral CT reduce artifacts from brachytherapy applicators? What are the advantages for dose calculation? What are the current limitations?...

**Response:**
> # Spectral CT for Brachytherapy Planning## OverviewSpectral CT (dual-energy CT) uses two different X-ray energy spectra to differentiate materials based on their attenuation characteristics. This technology has several potential applications in brachytherapy planning.## How Spectral CT Improves Material Characterization| Feature | Conventional CT | Spectral CT ||---------|-----------------|-------------|| Single energy measurement | HU at one kV | HU at multiple energies || Material decomposition | Limited | iodine/water/bone separation || Electron density | Assumes water equivalence | Direct measurement || Effective atomic number | Indirect estimate | Calculated |**Key parameters extracted:**- **Iodine density maps...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1744](../screenshots/02_Q1744.png)

---

### ✅ Q1745

**Input:** I need to understand how to perform quality assurance for deformable image registration in adaptive brachytherapy. What phantom-based QA tests should I perform? How do I quantify registration accuracy? What are the acceptable accuracy criteria for pelvic DIR in brachytherapy? How often should I perform DIR QA?...

**Response:**
> # Quality Assurance for Deformable Image Registration in Adaptive Brachytherapy## 1. Phantom-Based QA Tests### Physical Phantoms| Phantom Type | Purpose | Key Features ||--------------|---------|--------------|| **Anthropomorphic pelvic phantom** | Simulate clinical conditions | Contains identifiable landmarks (bony anatomy, soft tissue, bladder, rectum) || **Point-landmark phantom** | Measure TRE (Target Registration Error) | ≥15 embedded markers visible on CT and MRI || **Deformable tissue phantom** | Test tissue deformation accuracy | Gel or elastic materials that can be deformed || **Applicator phantom** | Test applicator-based DIR | Contains brachytherapy applicator for CT/MRI |### Recommended Phantom Tests1. **Land...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1745](../screenshots/02_Q1745.png)

---

### ✅ Q1746

**Input:** I am performing brachytherapy planning for a pediatric patient with a pelvic rhabdomyosarcoma. What imaging considerations are specific to pediatric brachytherapy? How do I minimize radiation exposure from imaging in a child? What MRI protocols are appropriate for pediatric pelvic brachytherapy? How do I account for smaller anatomy and developing organs in image-based planning?...

**Response:**
> # Pediatric Pelvic Brachytherapy Imaging: Comprehensive Guide## 1. Imaging Considerations Specific to Pediatric Brachytherapy### Radiation Exposure ConcernsChildren are significantly more radiosensitive than adults due to:- Higher proportion of dividing cells- Longer life expectancy allowing radiation effects to manifest- Developing organs with higher vulnerability to radiation damage**CT Imaging Principles:**| Parameter | Recommendation ||-----------|----------------|| Slice thickness | 1-2 mm (reconstructed) to minimize partial volume effects in small structures || kVp | Lower settings (80-100 kVp) appropriate for smaller body habitus || mAs | ALARA principle — use lowest mAs that provides diagnostic quality || Scan range | Minimize to area of interest only || Contrast | Use gadolinium-based MRI contrast rather than iodinated CT contrast when possible...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1746](../screenshots/02_Q1746.png)

---

### ✅ Q1747

**Input:** I need to understand the concept of online adaptive brachytherapy using MR-Linac technology. How can an MR-Linac be used for brachytherapy? What are the advantages of real-time MRI guidance during brachytherapy? How does online adaptive planning work? What are the current limitations and clinical evidence for MR-Linac brachytherapy?...

**Response:**
> ## Online Adaptive Brachytherapy Using MR-Linac Technology### OverviewMR-Linac systems (Elekta Unity, ViewRay MRIdian) combine a linear accelerator with a MRI scanner. While primarily designed for external beam radiation therapy (EBRT), MR-Linac technology offers insights for adaptive brachytherapy through:**Direct Brachytherapy Application (Limited):**- MR-Linac is not a brachytherapy delivery system- It can be used for **external beam boost** before or after brachytherapy- Real-time MRI tracking during EBRT mimics adaptive principles used in IGABT### Advantages of Real-Time MRI Guidance| Advantage | Application ||-----------|-------------|| Soft tissue visualization | Accurate target delineation without fiducials || No ionizing radiation imaging | Reduced cumulative dose...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1747](../screenshots/02_Q1747.png)

---

### ✅ Q1748

**Input:** I am evaluating the use of emerging imaging technologies for brachytherapy guidance. Are there any novel imaging modalities that could improve brachytherapy planning? What are the current research directions in brachytherapy imaging? How might photoacoustic imaging or optical coherence tomography be applied to brachytherapy? What is the timeline for clinical implementation?...

**Response:**
> Based on current research, here are the emerging imaging modalities for brachytherapy guidance:## Novel Imaging Modalities### Photoacoustic Imaging (PAI)- **Mechanism**: Uses laser-induced ultrasound to detect optical absorption contrast- **Advantages**: Can visualize blood vessels, oxygenated vs deoxygenated hemoglobin- **Brachytherapy applications**: Real-time soft tissue visualization, vascular mapping near applicators- **Research status**: Preclinical/early clinical validation [PubMed: 30923674]### Optical Coherence Tomography (OCT)- **Mechanism**: Uses near-infrared light to create high-resolution cross-sectional images- **Advantages**: Microscopic resolution (~10 μm), no radiation- **Brachytherapy applications**: Surface/interstitial tissue characterization, applicator-tissue interface visualization- **Research status**: Investigational for gynecologic and superficial applications...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1748](../screenshots/02_Q1748.png)

---

### ✅ Q1749

**Input:** I need to understand how to perform image quality assessment for brachytherapy planning CT. What metrics should I use to evaluate CT image quality? How do I measure spatial resolution, contrast resolution, and noise? How do these quality parameters affect brachytherapy dose calculation? What are the minimum image quality requirements for brachytherapy planning?...

**Response:**
> ## CT Image Quality Assessment for Brachytherapy Planning### Key Image Quality Metrics| Metric | Measurement Method | Brachytherapy Relevance ||--------|-------------------|------------------------|| **Spatial Resolution** | MTF (Modulation Transfer Function), line-pair phantom | Affects applicator edge visualization, seed localization accuracy || **Contrast Resolution** | Low-contrast detectability phantom | Tumor vs. soft tissue delineation || **Noise** | SD of HU in uniform region (water) | Low contrast OAR boundaries || **Slice Thickness** | Directly measured | Volume accuracy, partial volume effects || **Geometric Accuracy** | Distance markers, phantom landmarks | Applicator reconstruction precision...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1749](../screenshots/02_Q1749.png)

---

### ✅ Q1750

**Input:** I am reviewing a brachytherapy plan where the planning CT shows significant bowel gas in the pelvis. How does bowel gas affect brachytherapy dose calculation? What strategies can I use to minimize bowel gas during CT simulation? How should I handle bowel gas in the treatment planning system? Should I consider repeating the CT scan?...

**Response:**
> ## Bowel Gas in Brachytherapy Planning CT### Impact on Dose Calculation**CT Number Artifact:**- Bowel gas creates HU values of approximately -1000 to -200 (similar to air)- Modern brachytherapy dose algorithms assume homogeneous soft tissue between applicator and OARs- Gas pockets can cause significant errors in calculated dose to organs at risk (rectum, sigmoid, small bowel)**Dose Calculation Effects:**- **Underestimation of OAR doses**: Gas between applicator and rectum/sigmoid causes the TPS to calculate less attenuation, resulting in reported doses **5-15% lower** than actual delivered dose- **Applicator visualization**: Gas near applicator tips can obscure visualization and cause reconstruction errors- **Hot spot artifact**: Air-tissue interfaces create dose perturbations that TPS may...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1750](../screenshots/02_Q1750.png)

---

